REGN
Price
$919.96
Change
+$15.61 (+1.73%)
Updated
Nov 9 closing price
Capitalization
93.11B
80 days until earnings call
Intraday BUY SELL Signals
SLXN
Price
$0.12
Change
-$0.03 (-20.00%)
Updated
Nov 9 closing price
Capitalization
827.37K
One day until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

REGN vs SLXN

REGN vs SLXN Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
REGN vs. SLXN commentary
Nov 10, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is REGN is a Buy and SLXN is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for REGN with price predictions
Nov 09, 2026

REGN in upward trend: 10-day moving average crossed above 50-day moving average on October 26, 2026

The 10-day moving average for REGN crossed bullishly above the 50-day moving average on October 26, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on REGN as a result. In 62 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 68%.

The Moving Average Convergence Divergence (MACD) for REGN just turned positive on October 14, 2026. Looking at past instances where REGN's MACD turned positive, the stock continued to rise in 33 of 50 cases over the following month. The odds of a continued upward trend are 66%.

REGN moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where REGN advanced for three days, in 203 of 315 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

The Aroon Indicator entered an Uptrend today. In 186 of 264 cases where REGN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Bearish Trend Analysis

The 10-day RSI Indicator for REGN moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 44 similar instances where the indicator moved out of overbought territory. In 21 of the 44 cases, the stock moved lower in the following days. This puts the odds of a move lower at 48%.

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 40 of 64 cases where REGN's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 62%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where REGN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 57%.

REGN broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 7 (best 1 - 100 worst), indicating outstanding price growth. REGN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 64 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.936) is normal, around the industry mean (3.498). P/E Ratio (21.599) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (1.238) is also within normal values, averaging (9.059). Dividend Yield (0.004) settles around the average of (130.981) among similar stocks. P/S Ratio (5.339) is also within normal values, averaging (440.869).

A.I.Advisor
a Summary for SLXN with price predictions
Nov 09, 2026

SLXN in -14.12% downward trend, sliding for three consecutive days on October 29, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SLXN declined for three days, in 186 of 202 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for SLXN entered a downward trend on November 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for SLXN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLXN advanced for three days, in 58 of 98 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.

SLXN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.804) is normal, around the industry mean (3.498). P/E Ratio (-0.007) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SLXN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SLXN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
REGN: Fundamental Ratings
REGN
OUTLOOK RATING
1..100
44
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
PROFIT vs RISK RATING
1..100
64
SMR RATING
1..100
59
PRICE GROWTH RATING
1..100
7
P/E GROWTH RATING
1..100
13
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
REGNSLXN
RSI
ODDS (%)
Bearish Trend 1 day ago
48%
Bullish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
63%
Bullish Trend 1 day ago
56%
Momentum
ODDS (%)
Bullish Trend 1 day ago
68%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
66%
N/A
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
57%
Bearish Trend 1 day ago
72%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
65%
Bearish Trend 1 day ago
81%
Advances
ODDS (%)
Bullish Trend 1 day ago
64%
Bullish Trend 6 days ago
59%
Declines
ODDS (%)
Bearish Trend 5 days ago
57%
Bearish Trend 12 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
67%
Aroon
ODDS (%)
Bullish Trend 1 day ago
70%
Bearish Trend 1 day ago
86%
COMPARISON
Comparison
Nov 10, 2026
Stock price -- (REGN: $919.96 vs. SLXN: $0.12)
Brand notoriety: REGN: Notable vs. SLXN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: REGN: 123% vs. SLXN: 13%
Market capitalization -- REGN: $93.11B vs. SLXN: $827.37K
REGN [@Biotechnology] is valued at $93.11B. SLXN’s [@Biotechnology] market capitalization is $827.37K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

REGN’s FA Score shows that 2 FA rating(s) are green while SLXN’s FA Score has 0 green FA rating(s).

  • REGN’s FA Score: 2 green, 3 red.
  • SLXN’s FA Score: 0 green, 5 red.
According to our system of comparison, REGN is a better buy in the long-term than SLXN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

REGN’s TA Score shows that 6 TA indicator(s) are bullish while SLXN’s TA Score has 4 bullish TA indicator(s).

  • REGN’s TA Score: 6 bullish, 4 bearish.
  • SLXN’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, REGN is a better buy in the short-term than SLXN.

Price Growth

REGN (@Biotechnology) experienced а -4.30% price change this week, while SLXN (@Biotechnology) price change was -16.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.23%. For the same industry, the average monthly price growth was -8.97%, and the average quarterly price growth was +85.13%.

Reported Earning Dates

REGN is expected to report earnings on Jan 29, 2027.

SLXN is expected to report earnings on Nov 11, 2026.

Industries' Descriptions

@Biotechnology (+2.23% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

REGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, REGN has been loosely correlated with VRTX. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if REGN jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To REGN
1D Price
Change %
REGN100%
+1.73%
VRTX - REGN
42%
Loosely correlated
+0.69%
EXEL - REGN
41%
Loosely correlated
+3.12%
RPRX - REGN
41%
Loosely correlated
+2.18%
INCY - REGN
39%
Loosely correlated
+1.87%
BMRN - REGN
35%
Loosely correlated
+2.05%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TDY643.3424.74
+4.00%
Teledyne Technologies
PJT152.283.67
+2.47%
PJT Partners
ZDAI1.30N/A
N/A
DirectBooking Technology Co. Ltd.
RRGB8.51-0.11
-1.28%
Red Robin Gourmet Burgers
NAVI7.84-0.58
-6.89%
Navient Holdings Inc